Shi-Yong Sun
Overview
Explore the profile of Shi-Yong Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
198
Citations
10273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang G, Pannucci A, Ivanov A, Switchenko J, Sun S, Sica G, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941812
To investigate the preclinical efficacy and identify predictive biomarkers of polo-like kinase 1 (PLK1) inhibitors in small cell lung cancer (SCLC) models. We tested the cytotoxicity of selective PLK1 inhibitors...
2.
Sharma R, Sharma S, Shriwas P, Mehta L, Vu A, Mouw J, et al.
iScience
. 2024 Nov;
27(11):111133.
PMID: 39524367
Non-small cell lung cancer (NSCLC) collective invasion is supported by cooperativity of proliferative (follower) and invasive (leader) cells. H1299-isolated follower cells exhibit higher Yes-associated protein (YAP) expression, while leader cells...
3.
Zhang N, Cai S, Wang M, Hu T, Schneider F, Sun S, et al.
Cell Mol Bioeng
. 2024 Nov;
17(5):467-490.
PMID: 39513000
Purpose: Current bulk molecular assays fail to capture spatial signaling activities in cancers, limiting our understanding of drug resistance mechanisms. We developed a graph-based super-resolution protein-protein interaction (GSR-PPI) technique to...
4.
Cai S, Hu T, Venkataraman A, Moctezuma F, Ozturk E, Zhang N, et al.
Nat Biomed Eng
. 2024 Oct;
PMID: 39478233
Protein-protein interactions (PPIs) regulate signalling pathways and cell phenotypes, and the visualization of spatially resolved dynamics of PPIs would thus shed light on the activation and crosstalk of signalling networks....
5.
Chen Z, Vallega K, Wang D, Quan Z, Fan S, Wang Q, et al.
J Exp Med
. 2024 Sep;
221(11).
PMID: 39297884
The inevitable acquired resistance to osimertinib (AZD9291), an FDA-approved third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR activating...
6.
7.
8.
Wang L, Yang H, Wang C, Wang M, Huang J, Nyunt T, et al.
FASEB J
. 2024 Sep;
38(17):e70013.
PMID: 39225365
Articular cartilage phenotypic homeostasis is crucial for life-long joint function, but the underlying cellular and molecular mechanisms governing chondrocyte stability remain poorly understood. Here, we show that the protein tyrosine...
9.
Chen Z, Vallega K, Boda V, Quan Z, Wang D, Fan S, et al.
Adv Sci (Weinh)
. 2024 Jul;
11(35):e2310126.
PMID: 39044361
There is an urgent need to fully understand the biology of third generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), particularly osimertinib, and to develop mechanism-driven strategies to manage their acquired resistance. Transient...
10.
Li Y, Yue P, Deng X, Ueda T, Fukunaga R, Khuri F, et al.
Neoplasia
. 2024 Jul;
56:101031.
PMID: 39029162
No abstract available.